What’s behind the proposed pullback on remote patient monitoringnews2026-07-23T13:56:47+00:00July 23rd, 2026|Endpoints News|
Repligen’s $1.5B buy for BioLife; BeOne’s $300M US expansion news2026-07-23T13:01:21+00:00July 23rd, 2026|Endpoints News|
Lilly’s triple agonist heads to regulators after two more Phase 3 obesity winsnews2026-07-23T11:11:18+00:00July 23rd, 2026|Endpoints News|
Roche says it is thoughtful on token use for AI, shelves a drug from Carmot buynews2026-07-23T11:03:14+00:00July 23rd, 2026|Endpoints News|
Exclusive: Obesity biotech Verdiva hires ex-Metsera CMO as crucial readouts nearnews2026-07-23T10:30:33+00:00July 23rd, 2026|Endpoints News|
Teladoc is moving beyond its single-visit roots with new launchnews2026-07-23T10:00:41+00:00July 23rd, 2026|Endpoints News|
FDA swiftly puts Makary era in the rearview mirrornews2026-07-22T19:02:19+00:00July 22nd, 2026|Endpoints News|
Former FDA cancer chief Pazdur says the agency should restructurenews2026-07-22T18:46:02+00:00July 22nd, 2026|Endpoints News|
FDA approves Nuvalent’s cancer drug, a week after GSK closed $10.6B buyoutnews2026-07-22T18:21:51+00:00July 22nd, 2026|Endpoints News|
Arrowhead’s gene silencer competitive with Ionis’ in triglyceride diseasenews2026-07-22T15:32:21+00:00July 22nd, 2026|Endpoints News|
